CLIA Kit for Sclerostin (SOST)
VBCH; Sclerosteosis
- UOM
- FOB US$ 605.00 US$ 864.00 US$ 3,888.00 US$ 7,344.00 US$ 60,480.00
- Quantity
Overview
Properties
- Product No.SCC864Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- ApplicationsChemiluminescent immunoassay for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryDevelopmental science
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant Sclerostin (SOST) and the recovery rates were calculated by comparing the measured value to the expected amount of Sclerostin (SOST) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 99-105 | 102 |
EDTA plasma(n=5) | 94-105 | 97 |
heparin plasma(n=5) | 86-94 | 90 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Sclerostin (SOST) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Sclerostin (SOST) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Sclerostin (SOST) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 90-104% | 79-95% | 83-104% | 95-104% |
EDTA plasma(n=5) | 82-98% | 78-88% | 94-102% | 91-105% |
heparin plasma(n=5) | 91-101% | 93-105% | 83-92% | 99-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
Detection Reagent B | 1×120µL | Assay Diluent B | 1×12mL |
Substrate A | 1×10mL | Substrate B | 1×2mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

Test principle
The microplate provided in this kit has been pre-coated with an antibody specific to Sclerostin (SOST). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Sclerostin (SOST). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Sclerostin (SOST) level in the sample or standard.;
Giveaways
Increment services
-
Single-component Reagents of Assay Kit
-
Lysis Buffer Specific for ELISA / CLIA
-
Quality Control of Kit
-
CLIA Kit Customized Service
-
Disease Model Customized Service
-
Serums Customized Service
-
TGFB1 Activation Reagent
-
Real Time PCR Experimental Service
-
Streptavidin
-
Fast blue Protein Stain solution
-
Single-component Reagents of FLIA Kit
-
Streptavidin-Agarose Beads
Citations
- Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in OsteocytesPubMed: 23357248
- Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytesPubmed: 23247536
- Serum Sclerostin in Adult High-Activity Patients with Juvenile Idiopathic ArthritisPubmed:Pmc4236454
- Early effects of tumor necrosis factor inhibition on bone homeostasis after soluble tumor necrosis factor receptor usePubmed:Pmc4219971
- The Anti-Osteoanabolic Function of Sclerostin is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5Pubmed:25640331
- DMP-1-mediatedPubMed: 26481310
- Effect of Mirtazapine on Rat Bone Tissue after OrchidectomyPubMed: 25871861
- The effect of levetiracetam on rat bone mineral density, bone structure and biochemical markers of bone metabolismPubmed:29428468
- EFFECTS OF DISEASE-MODIFYING ANTIRHEUMATIC DRUG TREATMENT ON PERIARTICULAR BONE REMODELING IN RHEUMATOID AND PSORIATIC …:
- Dobesity: relationship between vitamin d deficiency, obesity and sclerostin as a novel biomarker of bone metabolism
- Circulating Osteocyte‐Related Biomarkers (vitamin D, sclerostin, dickkopf-1), hepcidin, and oxidative stress markers in early breast cancer: their impact in …Pubmed: 33065276
- Long-Term Administration of Abacavir and Etravirine Impairs Semen Quality and Alters Redox System and Bone Metabolism in Growing Male Wistar Rats34373766